Preparation of formulations of angiotensin II AT1 receptors...

Details Preparation of formulations of angiotensin II AT1 receptors... Preparation of formulations of angiotensin II AT1 receptors...

2002-04-09

2010-12-28

Jiang, Shaojia Anna (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

Reexamination Certificate

active

07858597

ABSTRACT:
Preparation of AT1 receptors antagonists formulations using the cyclodextrins, their derivatives and/or biodegradable polymers for the treatment of arterial hypertension, other cardiovascular disease and their complications. Until now, no applications using the AT11receptor antagonists and cyclodextrins or derivatives and/or biodegradable polymers for the treatment of arterial hypertension, other cardiovascular diseases and their complications, was found in the technical state of art. The present invention is characterized by the combination of two different technologies: one is the molecular encapsulation of AT11receptor antagonists in cyclodextrins and the other is the microencapsulation in biodegradable polymers. It also comprises the increase of the effectiveness of the AT11receptor antagonists as well as an increase in their bio-availability. The present invention comprises a new more effective alternative for the treatment of arterial hypertension, other cardiovascular diseases and their complications.

REFERENCES:
patent: 4340598 (1982-07-01), Furukawa et al.
patent: 4576958 (1986-03-01), Wexler
patent: 4598070 (1986-07-01), Ohwaki et al.
patent: 4666705 (1987-05-01), DeCrosta et al.
patent: 4834985 (1989-05-01), Elger et al.
patent: 5064825 (1991-11-01), Chakravarty et al.
patent: 5073641 (1991-12-01), Bundgaard et al.
patent: 5128355 (1992-07-01), Carini et al.
patent: 5134127 (1992-07-01), Stella et al.
patent: 5138069 (1992-08-01), Carini et al.
patent: 5153197 (1992-10-01), Carini et al.
patent: 5155118 (1992-10-01), Carini et al.
patent: 5171748 (1992-12-01), Roberts et al.
patent: 5210079 (1993-05-01), Carini et al.
patent: 5256687 (1993-10-01), Becker et al.
patent: 5266583 (1993-11-01), Ohtawa
patent: 5472954 (1995-12-01), Loftsson
patent: 5519012 (1996-05-01), Fercej-Temeljotov et al.
patent: 5662935 (1997-09-01), Motta
patent: 5728402 (1998-03-01), Chen et al.
patent: 5756546 (1998-05-01), Pirotte et al.
patent: 5834432 (1998-11-01), Rodgers et al.
patent: 5859258 (1999-01-01), Breen et al.
patent: 5916883 (1999-06-01), Shalaby et al.
patent: 6087386 (2000-07-01), Chen et al.
patent: 6096772 (2000-08-01), Fandriks et al.
patent: 6178349 (2001-01-01), Kieval
patent: 6204256 (2001-03-01), Shalaby
patent: 6383471 (2002-05-01), Chen et al.
patent: 200012728 (2000-06-01), None
patent: 0253310 (1988-01-01), None
patent: 0500297 (1992-08-01), None
patent: 1153613 (2001-11-01), None
patent: 209658 (1994-10-01), None
patent: WO 98/20044 (1998-05-01), None
patent: WO 99/16437 (1999-04-01), None
patent: WO 00/37075 (2000-06-01), None
patent: WO 00/59475 (2000-10-01), None
patent: WO 01/10851 (2001-02-01), None
Ikeda et al, Journal of Controlled Release, 2000, 66, 271-280.
Gilding, D.K., Biodegradable Polymers, Biocompatibility of Clinical Implant Materials, Chapter 9, 1981, 209-231.
Ruddy et al, Angiotensin II Receptor Antagonists, 1999, pp. 621-633.
Uekama et al, Chem. Rev. 1988, 98, 2045-2076.
Langer et al, J. Biomater. Sci. Polymer Edn. 1993, 3(4), 315-333.
Gilding, Biodegradable Polymers, Biocompatibility of Clinical Implant Materials, 1981, Chapter 9, 209-231.
The Merck Index 12th edition, 1996, p. 954, entry # 5613.
Ruddy et al Angiotensin Receptor II Antagonists, 1999, pp. 621-633.
Uekama et al Chem. Rev. 1998, 98, 2045-76.
Gilding Biodegradable Polymers, Biocompatibility of Clinical Implant Materials, 1981, Chapter 9, 209-231.
Langer et al J. Biomater. Sci. Polymer Edn. 1993, 3(4), 315-333.
Kostis et al Angiotensin II Receptor Antagonists, 1999, 71, 621-633.
The Merck Manual, 16thedition, 1992, pp. 409, 446-448, 498-500, 1450-1452, 1724.
Uekama et al Journal of Controlled Release, 2000, 66, 271-280.
Gilding , Biodegradable Polymers, Biocompatibility of Clinical Implant Materials, 1981, Chapter 9, 209-231.
Uekama et al, (Chem. Rev. 1998, 98, 2045-76.
Szejtli, Medicinal Research Reviews, 1994, 14(3), 353-62.
Keipert et al, International J. Pharmaceutics, 1996, 142, 153-62.
Hirayama et al, Pharmaceutical Sciences, 1995, 1 517-520.
MacMahon, S. et al., Blood pressure, stroke, and coronary heart disease, Lancet 335:765-774, 1990.
Kannel, W.B. et al., Changing epidemiological features of cardiac failure, Br. Hear J 1994; 72 (suppl 3): S3-S9.
Oliveira, M.T. Clinical features and prognosis of patients with high congested heart failure, College of Medicine USP, 1999, considered english abstract only.
Kannel, W.B.; Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA 275:1571-1576, 1996.
The Fifth Report of the Joint National Committee on detection, evaluation, and treatment of High Blood Pressure. National Institute of Health; Arc, Intern, Med. 153:154-183, 1993.
Frohlich, E.D., Angiotensin converting enzyme inhibitors. Hypertension vol. 13, No. 5 (suppl I): 125-130, 1989.
Sasaki, K. et al., Cloning and expression of a complementary DNA enconding a bovine adrenal angiotensin II receptor type-1. Nature, 351:230-232, 1991.
Rey et al.; Report the Canadian Hypertension Society. Consensus Conference.3.Pharmacologic treatment of essential hypertension. Can. Med. Assoc. J. 157(9): 1245-1254, 1997; (3): 575-584, 1993.
Menard, J. Anthology of the renin angiotensin system: A one hundred reference approach to angiotensin II antagonists. J. Hypertension 11 (suppl 3): S3-S11, 1993.
Ganong, W. Neuropeptides in cardiovascular control. J. Hypertens 2(suppl 3): 15-22, 1984.
McIntyre, M. et al., Losartan, an orally active angiotensin Angiotensin II AT1 receptor antagonist: review of its efficacy and safety in essential hypertension. Pharmacol. Ther. 74(2):181-194, 1997.
Criscione, L. de Gasparo et al; Pharmacological profile of valsartan. Br. J. Pharmacol 110:761-771, 1993.
Shibouta, Y. et al; Pharmacological profile of a highly potent and long-acting angiotension II receptor antagonist, J. Pharmacol. Exp. Ther. 266:114, 1993.
Ruddy, Michael C. et al, Angiotensin II Receptor Antagonists. 71:621-633, 1999.
Fielitz, Activation of the Cardiac Renin-Angiotensin System and Increased Myocardial Collagen Expression in Human Aortic Valve Disease; Journal of the Amer. College of Cardiology; vol. 37, No. 5, Apr. 1999; 1443-9.
L. Szente and J. Szejtli, Highly soluble cyclodextrin derivatives, Adv. Drug Deliv. Rev. 36: 17-28, 1999.
Powell et al; A Review of the New Angiotensin II-Receptor Antagonist Irbesartan; Cardiovascular Drug Review; vol. 16, No. 3, 1998 pp. 169-194.
Tamada, et al; Review: The development of polyanhydrides for drug delivery applications; J. Biometer, Sci. Polymer Edn., vol. 3, No. 4, pp. 315-353; 1992.
Gilding; Biodegradable Polymers, Biocompatibility of Clinical Implant Materials; Chapter 9; pp. 209-231; 1981.
Wilson, P.W.; From hypertension to heart failure: what have we learned?; Clin Cardiol. 1999; Oct. 22; Suppl. 5VI-10; Abstract Only.
Lipkowitz et al., “Enantioselective Binding of Tryptophan by a-Cyclodextrin,” (1992) J. Am. Chem. Soc., vol. 114, pp. 1554-1562.
Blaschke et al., “Enantiomer Separation of Drugs by Capillary Electromigration Techniques,” (2000) J. Chromatography, vol. 875, pp. 3-25.

Affiliated with

Also associated with

Rating

Preparation of formulations of angiotensin II AT1 receptors... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Preparation of formulations of angiotensin II AT1 receptors..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Preparation of formulations of angiotensin II AT1 receptors... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4189301